申请人:Ono Pharmaceutical Co., Ltd.
公开号:US04346099A1
公开(公告)日:1982-08-24
The imidazole derivatives of the general formula: ##STR1## [wherein m represents an integer of 4 to 9, R.sup.1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, and one of R.sup.2 and R.sup.3 represents a hydrogen atom, and the other represents a halogen atom or a phenyl group, or R.sup.2 and R.sup.3 together represent --(CH.sub.2).sub.n --(in which n represents an integer of 4 to 6) or represent .dbd.CH.sub.2 ] and non-toxic salts thereof, which have a specifically inhibitory effect on the biosynthesis of thromboxane A.sub.2 (abbreviated as TXA.sub.2 hereafter) and are, therefore, useful as treating agents for diseases caused by TXA.sub.2 such as inflammation, cerebral apoplexy, myocardial infarction, acute cardiac death, cardiostenosis and thrombus etc.
通用公式的咪唑衍生物:##STR1## [其中m表示4到9的整数,R.sup.1表示氢原子或含有1到12个碳原子的直链或支链烷基,R.sup.2和R.sup.3中的一个表示氢原子,另一个表示卤原子或苯基,或R.sup.2和R.sup.3一起表示--(CH.sub.2).sub.n--(其中n表示4到6的整数)或表示.dbd.CH.sub.2]及其无毒盐,对血栓素A.sub.2(以下简称为TXA.sub.2)的生物合成具有特异性抑制作用,因此可用作治疗由TXA.sub.2引起的疾病的治疗剂,如炎症、脑卒中、心肌梗死、急性心脏死亡、心脏狭窄和血栓等。